TQ Therapeutics Acquires Juno Therapeutics GmbH, Bolstering Cell Therapy Development

Martinsried, Germany, May 28, 2025 – TQ Therapeutics GmbH (“TQx”), a biotechnology company dedicated to advancing cellular therapies through innovative technologies, today announced the acquisition of Juno Therapeutics GmbH (“Juno GmbH”). The acquisition was completed via a share purchase agreement with Juno GmbH, a German subsidiary of Juno Therapeutics, Inc., itself a wholly owned subsidiary of global biopharmaceutical company Bristol Myers Squibb. Financial terms of the agreement were not disclosed.

This strategic acquisition significantly enhances TQx’s capabilities and expands its access to crucial intellectual property and license agreements. These assets will support the accelerated development of the company’s potentially transformative cell processing platform.

TQx is focused on revolutionizing traditional cell therapy production, aiming for a decentralized, scalable, fast, and highly automated, cost-efficient approach.

“This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future,” said Dr. Christian Eckert, CEO of TQx. “This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients.”